Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10633576 | 0.92 | GAA (0.32) | FFAR1GPR84 | |
| SCHEMBL9228623 | 0.91 | NR1I2 (0.36) | GPR84 | |
| SCHEMBL3390190 | 0.88 | FFAR1 (0.31) | FFAR1GPR84 | |
| SCHEMBL22819103 | 0.86 | NR1I2 (0.38) | GPR84 | |
| SCHEMBL25866564 | 0.86 | NR1I2 (0.38) | GPR84 | |
| SCHEMBL21101056 | 0.86 | NR1I2 (0.38) | GPR84 | |
| SCHEMBL20098207 | 0.84 | NR1I2 (0.37) | GPR84 | |
| SCHEMBL19198110 | 0.84 | NR1I2 (0.37) | GPR84 | |
| SCHEMBL20372779 | 0.84 | NR1I2 (0.37) | GPR84 | |
| SCHEMBL5851068 | 0.83 | FFAR1 (0.42) | FFAR1GPR84NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | FFAR1 2840/4885GPR84 1120/4885ESR1 3638/4885 |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | MRPS23, RPP30, RPS19 | FFAR1 4101/4885GPR84 3786/4885ESR1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.